ResMed Inc. vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.99 (market cap $2.03B). The key difference: ResMed Inc. is far larger — about 15.7× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and ResMed Inc. pays a 1.16% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| RMD | TMF | |
|---|---|---|
Market Cap | $31.89B | $2.03B |
Volume | 618,314 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $275.96 | $44.14 |
52-Week Low | $182.82 | $25.19 |
Typical Hold Time | 51 Days | 28 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.92, up 2.73% with elevated volume. Technical indicators show a bearish trend from moving averages while oscillators are neutral. The stock faces strong resistance at $26-$27 levels with support at $25. Recent trading activity increased 5% to 5.24 million shares, indicating heightened investor interest in long-term Treasury exposure.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risk. The bearish technical setup suggests near-term pressure, while the neutral RSI indicates potential for stabilization. Investors should monitor interest rate trends and Federal Reserve policy as primary drivers of performance.
Trailing returns across standard periods
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →